Skip to main content
. Author manuscript; available in PMC: 2022 Apr 12.
Published in final edited form as: Curr Opin Chem Eng. 2021 Feb 5;31:100673. doi: 10.1016/j.coche.2021.100673

Figure 1.

Figure 1.

NC-based treatments for Synucleinopathies. A) Metal NCs are used as a carrier for therapeutic agents like siRNA to prevent overexpression and subsequent fibrillation B) Antibody strategies, both host and non-host derived, directly combating fibrillation C) Targeted NCs can further enhance delivery of therapeutics D) Lipid-based delivery of therapeutic compounds, including the ability to incoporate multiple therapeutics in the same formulation, e.g. multifunctional E) Metal NCs intrinsically act as therapeutics by directly interfering with fibril formation F) Polymeric NCs intrinsically act as therapeutics by restoring lysosome function